The U.S. Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading in the securities of Apotheca Biosciences Inc. (CBDC), of St. Petersburg, Florida, commencing at 9:30 a.m. EDT on July 1, 2019, and terminating at 11:59 p.m. EDT on July 15, 2019:

The Commission temporarily suspended trading in the securities of the foregoing company because of questions that have been raised about the accuracy and adequacy of publicly disseminated information concerning, among other things, corporate assets, anticipated corporate acquisitions, business operations, and up-listing to the OTCQB. This order was entered pursuant to Section 12(k) of the Exchange Act.

The Commission cautions brokers, dealers, shareholders and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by these companies.

Further, brokers and dealers should be alert to the fact that, pursuant to Exchange Act Rule 15c2-11, at the termination of the trading suspensions, no quotation may be entered relating to the securities of the subject companies unless and until the broker or dealer has strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to CBDC’s securities until such time as he has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

If any broker-dealer or other person has any information which may relate to this matter, the Boston office of the Securities and Exchange Commission should be telephoned at 617-573-8900. The SEC appreciates the assistance of the Financial Industry Regulatory Authority (FINRA).